Rayner acquires Omidria to expand surgical offering in USA and Europe

​Rayner Surgical Group (‘Rayner’) and Omeros Corporation (‘Omeros’) are delighted to announce the transfer of Omeros’ ophthalmology assets, including OmidriaTM, to Rayner. This will enable the creation of a significant commercial, regulatory and marketing infrastructure in the US, with a broad range of products, including intraocular lenses (IOLs), for cataract surgeons.

OmidriaTMhas excellent and substantial clinical data supporting the maintenance of mydriasis (a dilated pupil) during surgery, protection of the eye from cystoid macular oedema and the reduction of post-operative pain without the use of opioids.

OmidriaTMwas approved by the US FDA in 2015 and has since become a key product in surgeons’ arsenals. It was also granted EMA approval for marketing in Europe, and Rayner is excited to bring OmidriaTM to European ophthalmologists through its direct businesses across Europe.

Commenting on the transfer, Dr Vance Thompson, a leading US ophthalmologist and OmidriaTMuser said, “We appreciate the security and improved care delivered by OmidriaTM and are excited to see this combine with the Rayner IOL portfolio to create an important new partner for US cataract surgeons.”

Mr Allon Barsam, a prominent London based ophthalmologist remarked, “We work closely with Rayner on their advanced technology IOLs and I also worked on the original clinical studies of OmidriaTM. It’s great to see this product coming to Europe and is consistent with Rayner’s vision to provide superior visual outcomes.”

“Rayner has over 100 years of heritage in ophthalmology including designing and manufacturing the world’s first IOL with Sir Harold Ridley in 1949. In recent years the company has expanded its manufacturing and commercial presence, now selling in over 80 countries across the world with a significant direct presence in Europe. Our strategic focus is on visual outcomes and patient safety through a range of surgical products and eye drops. The inclusion of OmidriaTMinto the portfolio makes perfect sense and I am particularly excited to see the OmidriaTM commercial team join Rayner,” said Tim Clover, Rayner’s CEO.

The transaction is expected to complete, subject to clearances, by 31 December 2021. Rayner was advised by Rothschild & Co, Freshfields Bruckhaus Deringer, PWC, LEK Associates, Avalere Health and Emmetropes.